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Abstract
Background: Isolation of mesenchymal stem cells (MSCs) in equines, has been reported for different tissues
including bone marrow, adipose, umbilical cord, peripheral blood, and yolk sac. In regard to the MSCs derived from
synovial fluid (SF) or membrane (SM), there is data available for humans, dogs, pigs, goats and horses. Especially in
equines, these cells have being considered promising candidates for articular regeneration. Herein, we established
and characterized MSCs obtained from equine SF and SM. Samples were obtained during arthroscopy and cultured
using MEM (Minimum Essential Medium). MSCs were characterized by morphology and expression of specific
markers for stem cells, pluripotency, inflammation, and cell cycle.
Results: The medium MEM was more effective (97 % ± 2) to maintain both cultures. The cultures were composed
by adherent cells with fibroblast-like shape, which had a growth pattern represented by a sigmoidal curve. After the
expansion, the cells were analyzed by flow cytometry for stem cells, inflammatory, and cell cycle markers, and both
lineages showed significant expression of CD45, Oct3/4, Nanog, CD105, CD90, CD34, CD117, CD133, TRA-1-81, VEGF,
and LY6a. In contrast, there were differences in the cell cycle phases between the lineages, which was not observed
in relation to the mitochondrial electrical potential.
Conclusion: Given the large impact that joint pathology has on the athletic performance horses, our results
suggested that the SF and SM are promising sources of stem cells with satisfactory characteristics of growth and
gene expression that can be used in equine regenerative medicine.
Keywords: Stem cells, Synovial Fluid, Horse, Regenerative medicine
Background
Joint destruction, a consequence of the development
of inflammatory, degenerative, and rheumatic diseases,
leads to severe disabilities [1]. Its high prevalence and
impact on the ability to work, coupled with the high cost
of therapeutic procedures, makes it an important problem
for veterinary clinics. Horses that are intensely active, and
also have an especially high level of performance, are sus-
ceptible to musculoskeletal disorders, which can culmin-
ate in low athletic performance and pathologies [2]. These
injuries require a strategic clinical application to restore
the cartilage, bone, tendon, and muscles [3]. The synovial
fluid produced by the synovial membrane is viscous, light
yellow, clear, and free of particulate matter, fibrinogen and
other coagulation factors [4]. Despite being treated as an
inert material for decades, the articular cartilage is a tissue
in constant regeneration. In addition, data has shown that
the synovial membrane and fluid are sources of mesenchy-
mal progenitor cells, which support the ability of in vivo
cartilage repair [5]. Mesenchymal stem cells (MSCs) can
be defined as a population of adherent cells, fibroblastic in
shape, and multipotent with high proliferative abilities. Be-
sides the first stem cells were obtained from the bone
marrow, the continued search for new sources of stem
cells coupled with technological advances in cell isolation,
has allowed for the identification of mesenchymal stem
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cells from several adult tissues, such as periosteum, mus-
culoskeletal tissue, adipose, and the synovial membrane
and fluid [6]. Although bone marrow is considered a good
and acceptable source of stem cells, the synovial mem-
brane and its fluid are tissue-specific, which leads to a
chondrogenic and expansion potential greater than other
sources. Furthermore, these cells can be obtained by min-
imally invasive techniques [6–9]. Previously data demon-
strated the multipotency of stromal cells obtained from
the synovial fluid of horses with intraarticular injury and
synovitis [10]. The synovial fluid-derived MSCs expressed
CD90, CD105, CD44, CD11a/CD18, and MHC class I and
II. In addition, in vitro the cells were able to differentiate
in osteogenic, adipogenic, chondrogenic, and tenogenic
lineages [10]. Considering that treating osteoarthritis,
which causes persistent pain and contributes to chronic
lameness, is difficult in chronic diseases, with a reserved
prognosis [11–13], and the growing interest for this field
especially in regard to the search for new strategies for
treatment, we are establishing a protocol to culture and
characterize mesenchymal stem cells not only from equine
synovial fluid but also from the synovial membrane, which
in the future can be used to treat osteoarthritis, especially
when surgical intervention is not viable.
Methods
Sampling and cell culture
This research was approved by the Bioethics Committee
from the School of Veterinary Medicine and Animal
Science, University of Sao Paulo, Sao Paulo, Brazil
(Protocol 2771/2012). Synovial fluid and membrane
were obtained from the tibiotarsal and metacarpophalan-
geal joints during arthroscopic procedure in ten horses
with osteochondrosis, which were included in the research
after agreement of the owners. Samples were collected in
a sterile syringe and transferred to tissue culture flasks
(Corning, NY, USA) with 5 ml of culture medium MEM
(Minimum Essential Medium—GIBCO™), supplemented
with 10 % of fetal bovine serum (FBS) and 1 % of penicillin
and streptomycin. Culture flasks were incubated at 37 °C
with a relative humidity atmosphere of 5 % CO2. After 24
and 48 h, non-adherent cells were removed and the
medium was replaced. Every 3 days, 70 % of the
medium was replaced and at an 80 % confluence, the
cells were enzymatically dissociated using 0.25 % tryp-
sin (Invitrogen, Carlsbad, CA, USA) for 5 min at 37 °C.
Thereafter, the cells were centrifuged at 1000 rpm for
5 min and the pellet that resulted was resuspended in
1 ml of a culture medium and transferred to culture
flasks. The growth and morphology of the adherent
cells were followed by photo documentation in an
inverted microscopy (NIKON ECLIPSE TS-100),
coupled with an image system (CCD—Sony). For freezing,
cryotubes with 1 × 104 cells and freezing medium (90 % of
FBS and 10 % of DMSO) were maintained in liquid
nitrogen.
Growth curve
The growth curve was performed in order to evaluate
the expansion and replication abilities, standardize the
optimal cell concentration for cell growth, and assess
their kinetic behavior. After initially establishing the cul-
ture, samples were obtained during the periods of 24, 48,
72, 96, 120, 144, and 168 h. The evaluation of the cell
number and viability were performed in triplicate by cell
counting in the Neubauer chamber using Trypan Blue
0.2 % (v:v) staining.
Immunophenotyping by flow cytometry
Adherent cells on passage 7 were resuspended in FACS
(fluorescence-activated cell sorting) buffer, and the con-
centration adjusted to 105cells/mL. For intracytoplasmic
and nuclear markers, cells were permeabilized with 5 μl
0.1 % Triton X-100 for 30 min prior to incubation with
primary antibodies (concentration of 1:100) specific for
stem cells, inflammation, and cell cycle progression: Oct
3/4 (C-10, SC-5279), Nanog (n-17, SC-30331), CD45/
OX1 (SC-53045), CD105 (2Q1707, SC-71042), CD90
(Thy-1, aTHy-1A1), CD34 (BI-3C5, SC: 19621), Caspase-3
(SC-7272), HSP-47 (SC-8352), P21 (SC-6246), Ki67 (Ab –
15580), Cyclin-D1 (AB-27618), P53 (Ab −26), TRA-1-81
(SC-21706), MCP-1 (SC- 32771), TNF-R1 (SC, 52746), all
from Santa Cruz Biotechnology, as well as CD117 (c-Kit,
SCF-Receptor Ab-6, RB-1518-R7, Thermo Scientific, Lab
Vision Corporation, Fremont, CA, USA), VEGF-R1 (Clone
VG1, M7273, DakoCytomation, CA, USA), COX-2
(Cayman Chemical Co, EUA), CD11b (MCA-551FT),
Ly6a (Ab – 51317), CD1a (SC-18885), and CD133
(Mab4310, Merck Millipore), all for 45 min at room
temperature. Then, cells were incubated for 2 h with
a secondary antibody (Anti-Mouse FITC, DakoCyto-
mation, Santa Cruz Biotechnology). The analysis was
performed using a flow cytometer (FACSCalibur, BD).
The expression of surface markers was determined by
comparison with an isotype control analyzed by a histo-
gram on the CELLQUEST program.
Analysis of the cell cycle
For the evaluation of the cell cycle, cells were resus-
pended in FACS flow buffer and centrifuged for 3 min at
2000 rpm. The supernatant was discarded and the cells
were carefully resuspended in 1 ml of 70 % RNAse etha-
nol, transferred to microtubes and stored at −20 °C.
Then, samples were centrifuged again at 2000 rpm for
5 min and the cells were resuspended in 1 ml of cytome-
try buffer. After centrifugation, cells were resuspended
in a propidium iodide solution, which was prepared
using 5 ml of PBS (phosphate buffer solution), 5 μl of
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Triton 100 (0,01 % v/v), 50 μl of RNAse A (2 mg/ml)
and 20 μl of propidium iodide (5 mg/ml). The analysis
was performed using a FACSCalibur flow cytometry and
the Win 2.8 MDI program.
Analysis of the electrical potential of the mitochondrial
membrane
Rhodamine 123 (Invitrogen, EUA) was used for the
analysis of mitochondrial membrane potential (Δψm).
Cells from the synovial fluid and the membrane were
trypsinized and centrifuged at 1500 rpm for 10 min,
the supernatant was discarded and 5 μl of Rhodamine
123 (5 mg/ml) was added. Then, the cells were incu-
bated in CO2 (5 %) at 37 °C for 30 min. After this
period, the cells were centrifuged, the supernatant
was discarded, and the precipitate was resuspended
in 100 μl of buffer for FACsFlow cytometry (BD).
The analysis was performed on a FACSCalibur flow
cytometry (BD) and analyzed by the Win MDI 2.8
program.
Statistical analysis
The statistical analysis was performed using the ANOVA
test, followed by a multiple comparison test, TUKEY-
KRAMER. All values were expressed as mean ± standard
deviation (SD), considering as critical, the level for sig-
nificance values p < 0.05. Significant differences between
the groups were indicated by: ***p < 0.001; ** p < 0.01; *
p < 0.05. To perform the statistical analysis, the Graph-
Pad Prism version 5.0 was used.
Results
Morphology and culture growth
In order to standardize the best culture medium to
maintain the synovial fluid and membrane, 4 tests were
performed using 4 different types of mediums supple-
mented with 10 % of FBS and 1 % of antibiotics - peni-
cillin and streptomycin (Table 1). The mediums MEM
(Minimum Essential Medium) and DMEM-H (Dulbecco
Modified Essential Medium High Glucose) showed the
best results and were effective in maintaining the cells
with satisfactory characteristics of growth and in an un-
differentiated stage. As MEM was more effective (97 %
±2), this medium was chosen to culture the cells and
perform the experiments. Cells cultivated in mediums
RPMI-1640 (Roswell Park Memorial Institute) and
DMEM/F12 (Dulbecco Modified Eagle Medium) showed
unsatisfactory abilities for proliferation and growth.
However, in the culture, the cells also showed a
fibroblast-like morphology. Nevertheless, after the cul-
ture expansion, a loss of cell adhesion in the substrate
and development of multi-cell aggregates in the culture,
resulting in cell death, was observed (Table 1). Both cells
from the synovial fluid and the membrane had a
fibroblast-like appearance with a fusiform shape (Fig. 1a
and b) that was maintained after freezing. Cells were
cultivated until the 11th passage and showed the same
morphology during this period. Both, the synovial fluid
and membrane cells had a growth pattern represented
by a sigmoidal curve that reflected the phases of cell
adaptation under growing conditions, availability of
nutrients in the medium, and support for cell adhesion.
The synovial fluid cells showed a period of adjustment
in which proliferation does not occur, especially after
the addition of the cells to the culture medium. At
this stage there was an intense metabolic activity that
was dependent on density and cell adhesion. It corre-
sponded to the lag phase, with approximately 50 h of
culture. During the exponential growth phase, cell pro-
liferation was maximal and constant, occurring until
Table 1 Culture media used to isolate the mesenchymal stem cells derived from the equine synovial fluid and membrane
Medium Results
DMEM-High Glucose (LGC Biotecnologia, Cotia, Sao Paulo, Brazil), 10 % FBS (fetal bovine
serum) characterized (HyClone, Thermo Scientific), 1 % antibiotic solution (Penicilin G
10.00U mL, 25 mg mL, Streptomycin 10.000 mg mL), 1 % l-glutamine 200 Mm, and 1 %
non-essential amino acids. All from Invitrogen, Carlsbad, CA, USA
Quickly growth. Cells with fibroblast-like morphology. Cell
adhesion on plates. 80 ± 12 % of efficiency
MEM (LGC Biotecnologia, Cotia, Sao Paulo, Brazil), 10 % FBS characterized (HyClone,
Thermo Scientific), 1 % antibiotic solution (Penicilin G 10.00U mL, 25 mg mL,
Streptomycin 10.000 mg mL), 1 % l-glutamine 200 Mm, and 1 % non-essential amino
acids. All from Invitrogen, Carlsbad, CA, USA
Quickly growth. Cells with fibroblast-like morphology. Cell
adhesion on plates. 97 ± 2 % of efficiency
RPMI-1640 (LGC Biotecnologia, Cotia, Sao Paulo, Brazil), 10 % FBS characterized, 1 %
antibiotic solution (Penicilin G 10.00U mL, 25 mg mL, Streptomycin 10.000 mg mL),
1 % l-glutamine 200 Mm, and 1 % non-essential amino acids. All from Invitrogen,
Carlsbad, CA, USA. 1 % antibiotic solution (Penicilin G 10.00U mL, 25 mg mL, Streptomycin
10.000 mg mL), 1 % l-glutamine 200 Mm, and 1 % non-essential amino acids. All
from Invitrogen, Carlsbad, CA, USA
Slow growth. Cells with fibroblast-like morphology. Few
adhesion on plates. 10 ± 8.3 % of efficiency
DMEM/HAM’S-F12 (1:1) (LGC Biotecnologia, Cotia, Sao Paulo, Brazil), 10 % FBS
characterized, 1 % antibiotic solution (Penicilin G 10.00U mL, 25 mg mL, Streptomycin
10.000 mg mL), 1 % l-glutamine 200 Mm, and 1 % non-essential amino acids. All from
Invitrogen, Carlsbad, CA, USA
Slow growth. Cells with fibroblast-like morphology.
Unsatisfactory adhesion on plates. 5 ± 1.2 % of efficiency
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150 h of culture. The stationary phase, or plateau, when
the growth rate decreased, was not determined in these
culture conditions. However, cell death progressively
increased and cells detached from the substrate. After
168 h, there was a decline phase or cell death, which
showed a drastic decrease in density and cell viability.
The dose curve, time and cell density showed a signifi-
cant positive correlation, with r2 of 0.80 (Fig. 1c). In
relation to the growth of the synovial membrane cells,
the lag phase occurred after approximately 24 h of
culture. The exponential growth curve occurred from
50 to 150 h. In our culture condition, the stationary
phase also was not determined for synovial membrane
cells. In contrast, cell death and detachment of the
cells from the substrate progressively increased, as
demonstrated for synovial fluid cells. Finally, the de-
cline phase occurred close to 160 h, and the reduction
corresponded to 68 %. The dose curve, time and cell
density showed a significant positive correlation, with
r2 of 0.84 (Fig. 1d).
Immunophenotype, cell characterization, cell cycle
progression and proliferation rate
After the expansion, the cells obtained from synovial
fluid and membrane in the 7th passage were analyzed
by flow cytometry for stem cells, inflammatory, and cell
cycle progression markers. The cells showed a signifi-
cant expression of CD45 (35.7 and 57.8 %), Oct3/4
(31.8 and 43.3 %), Nanog (38.2 and 44.9 %), CD105
(34.5 and 32.5 %), CD90 (34.9 and 41.4 %), CD34 (34.6
and 34.6 %), CD117 (38 and 50.4 %), CD133 (43.5 and
70.9 %), TRA-1-81 (45 and 54.7 %), VEGF (37.2 and
47.9 %), and LY6a (42.8 and 35.6 %), respectively.
Representative dotplots of acquisition for each marker
by flow cytometry, and the mean and standard devi-
ation are shown on Figs. 2 and 3, for stem cells from
Fig. 1 Cell morphology and growth. a and (b): Both cells, from the synovial fluid and the membrane, respectively, had a fibroblast-like appearance
with a fusiform shape, growing in colonies. c and d: Both cultures had a growth pattern represented by a sigmoidal curve. The synovial fluid cells
(SF) showed a period of adjustment without proliferation (lag phase, approximately 50 h of culture). Exponential growth was observed until
150 h, and after 168 h a decline phase was observed (c). In contrast for synovial membrane cells (SM) the lag phase was reached approximately
24 h of culture, followed by a exponential growth until 150 h and a decline phase close to 160 h (d)
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Fig. 2 Expression of markers by flow cytometry on cells derived from the synovial fluid. The synovial fluid cells showed significant expression of
hematopoietic (CD45, CD34, CD117, and CD133), mesenchymal (CD105 and CD90), pluripotency (Oct3/4 and Nanog), embryonic (Tra-1-81), and
inflammatory (VEGF-R1 and LY6a) markers
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Fig. 3 Expression of markers by flow cytometry on cells derived from the synovial membrane. The synovial membrane cells showed significant
expression of hematopoietic (CD45, CD34, CD117, and CD133), mesenchymal (CD105 and CD90), pluripotency (Oct3/4 and Nanog), embryonic
(Tra-1-81), and inflammatory (VEGF-R1 and LY6a) markers
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the synovial fluid and membrane, respectively. Con-
firming the inflammatory potential of expression of the
VEGF-R1 receptor in synovial fluid cells, the expression
of pro-inflammatory markers was evaluated. The TNF-
R1 receptor, the chemotactic protein MCP-1 and CD1a
showed decreased expression in synovial membrane
cells, while the other analyzed markers (COX-2 and
CD11) did not show significant differences between the
synovial fluid and the membrane, despite being positive
in both colonies (Fig. 4). The HSP47, a collagen-specific
molecular chaperone responsible for the collagen
synthesis showed increased expression in the synovial
fluid cultures in comparison to the membrane. More-
over, high expression of Ki-67 was observed in both
cultures. The expression of other markers (Caspase-3,
p21, ciclin-D1, and p53) was similar between both
cultures (Fig. 4). For flow cytometry analysis, mouse
IgG2 and IgM were used as isotype controls (Fig. 5).
There were no significant differences in the proportions
of cell distribution in cell cycle phases between the
culture of synovial fluid cells of 48 and 144 h, showing
the maintenance of their proliferative potential, as
showed for the kinetics of cell growth and viability.
Representative histograms acquired by the ModFit pro-
gram of different cell cycle phases as well as the
comparison of the average values, are shown on Fig. 6a
and b. However, there were significant differences in
the proportions of synovial membrane cells between 48
and 144 h. There was a decrease in the G2/M cell popu-
lation, as demonstrated in the kinetics of cell growth
and viability. After 144 h, the synovial membrane cells
decreased their proliferative ability significantly. Repre-
sentative histograms of cell cycle phases, as well as the
average values, are shown on Fig. 6c and d. The proto-
col used with the CSFE demonstrated how the marker
was equally divided between the daughter cells during
each cell division. The results showed a higher capacity
for proliferation of synovial fluid cells between 48 and
144 h when compared to synovial membrane cells,
which showed lower proliferation after 144 h in culture.
Fig. 4 Expression of inflammatory and cell cycle progression markers by flow cytometry on cells derived from the synovial fluid and membrane.
The TNF-r, MCP-1 and CD1a were significantly reduced in the synovial membrane cells compared to the synovial fluid cells. There was no difference in
relation to the expression of the other markers (Cox-2 and CD11) between the two cultures and all markers showed significant expression. In relation
to cell cycle progression markers, statistical difference between the cultures was observed only in relation to the expression of HSP47, which was
increased in the synovial fluid cultures. The expression of other markers (Caspase-3, p21, Ki67, ciclin-D1, and p53) was similar between both cultures
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The acquisitions obtained by a flow cytometer were an-
alyzed by the Wizard Proliferation (Fig. 6e).
Analysis of mitochondrial electrical potential
The synovial fluid and membrane cells were sub-
jected to an analysis of the mitochondrial membrane
potential by Rhodamine 123 fluorochrome. After the
acquisition and analysis using the WinMDI program,
both synovial fluid and membrane cells cultivated
after 48 and 144 h did not show differences in the
electric potential. The representative histograms ob-
tained by a flow cytometer, and the means of popula-
tions with high electric potential (MI) and low
mitochondrial electrical potential (M2) are shown on
Fig. 7. The distribution of the mitochondrial number
per cell was also analyzed by considering the median
fluorescence intensity per cell. The dotplots of both
synovial fluid and membrane cells are shown on
Fig. 6. Data obtained from both cultures after 48 and
144 h showed that there were a significant number of
Fig. 5 Isotype controls. a and (b) Red line corresponds to the IgG2a isotype control (mouse) and in black the specific binding in samples of
synovial membrane and fluid, respectively. c and (d) Red line corresponds to the IgM isotype control (mouse) and in black the specific binding in
samples of synovial membrane and fluid, respectively
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Fig. 6 (See legend on next page.)
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Fig. 7 Analysis of mitochondrial electrical potential. Both synovial fluid (SF) and membrane (SM) cells cultivated after 48 and 144 h did not
show differences in the electric potential. The representative histograms obtained by a flow cytometer, show the means of populations with
high electric potential (MI) and low mitochondrial electrical potential (M2). In relation to the distribution of the mitochondrial number per
cell, data obtained from both cultures after 48 and 144 h showed that there were a significant number of mitochondria per cell, however,
without significant differences. Acquisition and analysis were performed using the WinMDI program
(See figure on previous page.)
Fig. 6 Analysis of the cell cycle on cells cultures derived from the synovial fluid and membrane. There were no significant differences in the
proportions of cell distribution in cell cycle phases between the culture of synovial fluid (SF) cells of 48 and 144 h (a and b). In contrast, there were
significant differences in the proportions of synovial membrane (SM) cells between 48 and 144 h. There was a decrease in the G2/M cell population, as
demonstrated in the kinetics of cell growth and viability. After 144 h, the synovial membrane cells decreased their proliferative ability (c and d). e: The
results showed a higher capacity for proliferation of synovial fluid (SF) cells between 48 and 144 h when compared to synovial membrane (SM) cells,
which showed lower proliferation after 144 h in culture. The acquisitions were obtained by flow cytometer were analyzed by the Wizard Proliferation
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mitochondria per cell, however, without significant
differences (Fig. 7).
Discussion
Damage in the articular cartilage requires therapeutics
innovations that can repair the structure of this tissue in
order to offer an efficient treatment for patients. Cur-
rently, cell therapy is an essential tool and an important
alternative for regenerative medicine. Advances in the
development of cell culture allow the development of a
variety of culture mediums supplemented with growth
factors, amino acids, and several other substances. The
best results to cultivate the cells obtained from the
synovial fluid and membrane were obtained using MEM
(Minimum Essential Medium) and DMEM-H (Dulbecco’s
Modified Essential Medium High Glucose), which were
effective in maintaining the cells in an undifferentiated
and proliferative stage with satisfactory characteristics
of growth as previously discussed in the literature [6, 7,
13]. After expansion, freezing, and culture, synovial
fluid- and membrane-derived cells were extended to the
11th passage. But, the cells in the 7th passage were ana-
lyzed in relation to the morphological and functional as-
pects. Human adult cells were able to retain a linear
growth curve for at least 30 replications [6]. As we dem-
onstrated in our results, though we studied the kinetics
of different cells in the 7th passage, the authors also ob-
tained a sigmoidal growth curve. According to De Bari
et al. [1] the multipotent capacity of the cells is not in-
fluenced by donor age, cell passage and cryopreserva-
tion. In addition, they described these cells as showing a
limited senescence and able to be expanded to large
numbers of cultures. This study demonstrated that hu-
man cells maintained their proliferative capacity after
the 10th passage. However, in our study we were able to
cultivate the equine cells with satisfactory growth and
proliferation until the 11th passage. In addition, was
demonstrated that synovial fluid-derived MSCs isolated
from diseased joints proliferated to >1 × 106 cells at pas-
sage 3 and 1 × 107 cells at passage 4 [10]. It has been
shown that the synovial tissue can be obtained from dif-
ferent locations on the knee joint [14]. However, it is
known that cells derived from the medial limb have
more ability to form colonies than those collected from
other regions [13]. According to this, we obtained sam-
ples of the synovial membrane and fluid from the tibio-
tarsal and metacarpophalangeal joints. As stated by
Koga et al. [15], synovial fluid cells have higher chon-
drogenic potential, since they have a high production of
UDPGD, an enzyme necessary for the production of
HA, and are not expressed by other types of stem cells.
Besides that, elevated expression of specific markers for
chondrogenesis on horse synovial fluid-derived MSCs,
such as Sox-9, Col-II, and aggrecan were observed by
RT-PCR, as well as cartilage-specific molecules such as
COMP in the extracellular matrix [10]. It is known that
phenotypic characteristics, such as the production of
collagen type II, aggrecan and potential for osteogenic,
adipogenic, and chondrogenic differentiation is shared
between stem cells obtained from the synovial mem-
brane and fluid [15]. In vitro differentiation of horse
synovial fluid-derived MSCs demonstrated the multipo-
tency of these cells in osteogenic, adipogenic, chondro-
genic, and tenogenic differentiation [10]. In our study,
both synovial fluid- and membrane-derived cells demon-
strated similar characteristics during the culture and
expression of cell markers. Usually, the human mesenchy-
mal stem cells are characterized by the expression of
CD105, CD90, Stro-1, and CD73. In addition, this cell type
is negative for CD45, CD34, and CD11 [16–18]. Moreover,
Kolf et al. [19] stated that the co-expression of STRO-1,
CD73 and CD106 is the most efficient combination of
markers for mesenchymal stem cells. Krawetz et al. [20]
demonstrated that human synovial fluid-derived cells from
normal, healthy joints, and from joints with osteoarthritis
expressed CD105, CD73 (specific for mesenchymal stem
cells) and CD44 (a receptor for hyaluronic acid that can
also interact with collagens and MMPs, and can also be
expressed in mesenchymal stem cells). In addition, the
cells were negative to CD45RO, CD11, and CD34. Herein,
we showed that in equines, both the synovial fluid- and
membrane-derived cells expressed CD105, CD90, as well
as CD117 and CD133. Previously data [10, 21–23] demon-
strated that cells derived from these two tissues have a
phenotype similar to the bone marrow stem cells, in-
cluding the expression of CD105, CD90, CD44, and are
negative for CD45, CD34 and CD117. In contrast to
what is described for horse synovial fluid-derived MSCs
[10], our cell lineages had a significant expression of
CD45 and CD34, markers that are usually associated to
characterize hematopoietic cell lineages. Since, for horses,
an immunophenotype for stem cells is not established
[16], variations may occur, and it is important to consider
the influence of the severity and the acute our chronic
stage of the osteochondrosis in the expression of these
markers. The expression of CD117, also suggests the
hematopoietic capacity of this cell population, as well as
the VEGF-R1 receptor being an important mediator in the
recruitment, mobilization, angiogenesis and inflammation
of cells with a pluripotent potential. Krawetz et al. [20]
showed that CD90+ cells have increased chondrogenic
potential when compared to the CD90− cells. As demon-
strated by Nagase et al. [13], CD90 is expressed in
40–60 % of the cells during the first 7 days in culture
followed by a gradually decreased expression. Interest-
ingly, the chondrogenic potential also decreased, suggest-
ing that CD90 may be an important indicator of
chondrogenic differentiation. The significant difference
Prado et al. BMC Veterinary Research  (2015) 11:281 Page 11 of 13
between the expression of CD90 (≅38 %) in our results in
comparison to the literature (>90 %) [10] may be ex-
plained by the difference in the cell passages used in both
studies, passage 7 in our experiments in contrast to pas-
sage 4 used by Murata et al. [10]. Other toti- and multipo-
tency markers, OCT3/4, NANOG, and TRA-1-81,
significantly expressed in our cell population, showed no
difference between the synovial fluid and membrane. Al-
though similar regulatory mechanism has been suggested
for Oct4 in both embryonic and mesenchymal stem cells
[24], so far, little is known about the functional role of the
pluripotency markers, such as Oct4 and Nanog in adult
stem cells [25]. However, the synovial fluid and membrane
appear to be a source of stem cells with pluripotency po-
tential, as previously demonstrated [10]. Lee et al. [9] de-
veloped a gel composed of collagen type I, hyaluronic
acid, and fibrinogen, that encapsulates the cells derived
from the membrane to be used to repair the articular car-
tilage in rats. In addition, the authors stated that direct cell
transplantation without a matrix could induce a fibrosis
formation. According to Jones et al. [26] there is no differ-
ence in chondrogenic cells derived from healthy joints,
compared to osteoarthritis and rheumatoid arthritis.
Nevertheless, there is an increase in number of cells with
proliferative potential in joints with osteoarthritis due to
cell communication and release of growth and prolifera-
tive factors. This fact was confirmed demonstrating that
cells from individuals with osteoarthritis are 20 times
more numerous than those obtained from healthy pa-
tients. Morito et al. [27] demonstrated that stem cells are
increased in the synovial fluid of human beings with joint
disease and injury. In that regard, it was demonstrated for
horses that the number of colonies of synovial fluid-
derived MSCs from diseased joints at passage 0 was sig-
nificantly increased, when compared to normal joints,
suggesting that synovial fluid-derived MSCs could play an
important role in the process of degradation, repair, and
regeneration of damaged cartilage [10]. Inflammation,
which initiates in response to tissue injury, is complex and
highly regulated. Once activated, there is a sequential re-
lease of mediators which results in the development of
classic signs of inflammation: vasodilatation, increased
blood flow, higher temperature, and activation of sensory
pain [28]. Inflammatory cells are attracted to the area by
activating the expression of adhesion molecules [29]. For
the first time, it was investigated the expression of specific
markers involved in the inflammatory process on cells de-
rived from these tissues in horses. Our results showed that
there was a lower expression of the TNF-R1 receptor in
the synovial-derived cells, as well as of the chemotactic
protein MCP-1, when compared to synovial membrane-
derived cells. The other markers analyzed (COX-2, CD11
and CD1a) did not differ significantly in the cell cultures,
which can also justify the origin of the persistent
inflammatory joint. A decrease in the expression of TNF-
R1 was observed during the treatment of joints with goat
cells derived from the bone marrow after induced trauma
[30]. According to Kobayashi et al. [31] the TNF-R1 in-
duced the proliferation of synoviocytes from patients with
osteoarthritis. The expression and role of COX-2 were an-
alyzed in a model of acute arthritis [29], showing that this
marker correlates to the signs of the disease. We also
showed the expression of that in our cells, but without dif-
ferences between the synovial fluid- and membrane-
derived cells. The MCP-1 is expressed in individuals with
disorders in the temporomandibular joint and the values
were higher in patients with pain [32]. In addition, re-
cently, it was showed that horse synovial fluid-derived
MSCs were strongly positive for MHC class I and moder-
ately for MHC class II [10]. Synovial fluid and membrane
cultures showed a significant increase in the expression of
Ki67, which is involved in proliferation. It is expressed in
phases G1, S, G2, and M. There was a significant decrease
in the population of cells in G2/M, which confirms the re-
sults of the kinetics of cell growth and viability, where the
synovial membrane maintained in culture was significantly
reduced, including its proliferative capacity after 144 h of
culture. The increased expression of Ki67 was demon-
strated also on cells obtained from human osteochon-
droma [33]. The chaperone HSP-47, responsible for the
synthesis of collagen-remodeling proteins and chondro-
genic activity, was expressed in both cell types. This heat
shock protein is essential for the organization of cartilage
and normal endochondral bone formation [34]. However,
our data showed that the expression of HSP-47 was sig-
nificantly higher in synovial fluid-derived cells, indicating
that these cells are more efficient for collagen maturation
and chondrogenic activity than replicating cell death.
Izquierdo et al. [35] studied the expression of HSP-47 in
cells obtained from human rheumatoid arthritis, showing
that its expression can suggest the stage of the disease. Fi-
nally, damage of mitochondrial genome causes mutations
or deletions of mitochondrial gene products, leading to an
increase in the concentration of reduced respiratory chain
intermediates, resulting in the formation of free radicals
by self-oxidation. A vicious cycle is proposed: mitochon-
drial DNA damage affects the respiratory chain function,
leading to generation of more free radicals which, in turn,
will lead to further damage to mitochondrial DNA [36].
Our results showed a significant amount of mitochondria
distributed throughout the cell lines. The presence of ac-
tive mitochondria in the synovial fluid and membrane-
derived cells confirms their high proliferative capacity.
Conclusion
In conclusion, we confirmed the mesenchymal nature of
the synovial fluid- and membrane-derived stem cells by
the expression of specific markers as well as the capacity
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of both cell lineages to be used as a new strategy for cell
therapy, especially to treat joint pathologies in order to
repair cartilage defects or to be used in articular regener-
ation with a minimal invasiveness process.
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